The primary treatment for prolactinomas is dopamine agonist, while transsphenoidal surgery is recommended as primary therapy for the non-prolactinomas. This study aimed to evaluate the radiomic model in the differentiation of prolactinoma from non-prolactinomas before surgery. Our results demonstrated that the eXtreme Gradient Boosting model based on 2264 radiomic features extracted from the original and preprocessed sagittal contrast-enhanced T1WI and coronal T2WI yielded the AUC value of 1.000 and 0.828 on the train set and test set, respectively. The radiomic model may have potential for differentiating the prolactinomas from non-prolactinomas, which may be beneficial to guide the treatment plan.
This abstract and the presentation materials are available to members only; a login is required.